Aqilion AB has sold rights to its TAK1 inhibitors to Merck KGaA in an exclusive license and research collaboration agreement worth at least €960 million (US$1.03 billion) including potential milestones and royalties. The global giant will pay the Swedish biotech – which is headquartered in Helsingborg – €10 million in cash up front for the program and potential development and commercialization milestones and tiered royalties on worldwide net sales of more than €950 million.
Boston Immune Technologies and Therapeutics Inc. (BITT) has announced progress using its Domab platform. Two Domab CD40 antagonists, BITT-CD4D11 and BITT-CD4F10, have completed discovery and optimization and a final candidate is being selected for IND-enabling steps.
Researchers from The Salk Institute have described a signaling pathway that sets off an unusual, autophagy-dependent cell death mechanism as a fail-safe for cells that have evaded senescence mechanisms. The scientists found a tumor suppression mechanism mediated by telomere signaling, which activated an innate immune response through mitochondrial and telomere complexes to eliminate cells with shortened telomeres.
Scripps Research Institute and Shangpharma Innovation have divulged cyclic GMP-AMP synthase (MB21D1; cGAS) inhibitors reported to be useful for the treatment of autoinflammatory interferonopathy, autoimmune and neurological disorders.
Researchers from Jouf University and affiliated organizations have reported the discovery of novel cyclooxygenase-2 (COX-2) inhibitors as potential nonacidic anti-inflammatory agents.
In a blow to Aussie regenerative medicine company Regeneus Ltd., Japan’s Kyocera Corp. has pulled out of a licensing deal for Regeneus’ lead mesenchymal stem cell (MSC) therapy, Progenza, for osteoarthritis of the knee for the Japan market.
Inmagene Biopharmaceuticals Co. Ltd. has obtained IND approval from the FDA for IMG-008, the company's novel long-acting antagonistic humanized monoclonal antibody that specifically targets human IL-36 receptor (IL-36R) to treat auto-inflammatory diseases.
In a blow to Aussie regenerative medicine company Regeneus Ltd., Japan’s Kyocera Corp. has pulled out of a licensing deal for Regeneus’ lead mesenchymal stem cell (MSC) therapy, Progenza, for osteoarthritis of the knee for the Japan market. Osteoarthritis of the knee is the first indication for Progenza, an allogeneic off-the-shelf adipose-derived MSC therapy.
RSS
